Colon and rectal cancer
Conditions
Interventions
None listed
Sponsors
Tanabe Hirokazu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria will be enrolled. 1) During the enrollment period (December 1, 2019 to March 31, 2024), there is a prescription for either Avastin or Bevacizumab BS "Daiichi Sankyo". The earliest date of prescription of the Avastin or Bevacizumab BS "Daiichi Sankyo" during the enrollment period will be defined as the "cohort entry date". 2) There is a diagnosis of colon or rectal cancer during on the same month as the cohort entry date. 3) The earliest medical record date after the data period start date is at least 90 days before the cohort entry date.
Exclusion criteria
Exclusion criteria: Exclude patients who meet any of the following criteria: 1) There are prescriptions of bevacizumab (Bevacizumab BS "Daiichi Sankyo", Avastin, other bevacizumab) from the start of the survey period to the day before the cohort entry date. 2) There is a diagnosis of cancer except for colon or rectal cancer during on the same month as the cohort entry date. 3) There is a diagnosis of hypertension that meets the outcome definition from the start of the survey period to the day before the cohort entry date. 4) There are several prescriptions of bevacizumab (Bevacizumab BS "Daiichi Sankyo", Avastin, other bevacizumab) on the cohort entry date. 5) There is no medical record after the day following the cohort entry date.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence of hypertension | — |
Secondary
| Measure | Time frame |
|---|---|
| Other safety specification | — |
Contacts
Public ContactGPSP Contact
Daiichi Sankyo Co.,Ltd.
Outcome results
None listed